HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Receivables - Net (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Receivables - Net came in at $117.6 million in Q2 2026, down 20.01% year-over-year from $147.0 million in Q2 2025, and down 7.25% quarter-over-quarter from $126.8 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Receivables - Net (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Receivables - Net for 12 consecutive years, with $117.6 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Receivables - Net fell 20.01% year-over-year to $117.6 million in Q2 2026; TTM through Jun 2026 was $117.6 million, a 20.01% decrease from a year earlier, with the FY2025 full-year figure at $126.8 million, changed N/A from the prior year.
  • Receivables - Net was $117.6 million for Q2 2026 at HUTCHMED (China), down from $126.8 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $156.9 million in Q2 2024 and troughed at $8.6 million in Q4 2023.
  • A 5-year average of $96.9 million and a median of $122.2 million in 2025 frame the typical range for Receivables - Net.
  • Across the five-year window, Receivables - Net surged 313.05% in 2022 and fell 27.66% in 2023, its largest moves.
  • Over 5 years, Receivables - Net stood at $11.9 million in 2022, then slipped by 27.66% to $8.6 million in 2023, then surged by 1719.53% to $156.9 million in 2024, then decreased by 19.22% to $126.8 million in 2025, then retreated by 7.25% to $117.6 million in 2026.
  • The last three Receivables - Net figures came in at $117.6 million (Q2 2026), $126.8 million (Q4 2025), and $147.0 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.51 Bn 197.52 Bn 7.24 Bn
2 Gilead Sciences 181.48 Bn 178.30 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.45 Bn 124.60 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn
6 Moderna 54.72 Bn 49.59 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn
9 Roivant Sciences 30.31 Bn 30.31 Bn 1.16 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 117.56 Mn
Dec 31, 2025 126.75 Mn
Jun 30, 2025 146.97 Mn
Jun 30, 2024 156.92 Mn
Dec 31, 2023 8.62 Mn
Jun 30, 2023 129.20 Mn
Dec 31, 2022 11.92 Mn
Jun 30, 2022 77.08 Mn
Dec 31, 2021 -5.60 Mn
Jun 30, 2021 57.98 Mn
Mar 31, 2021 53.13 Mn
Dec 31, 2020 -9.60 Mn
Jun 30, 2020 44.63 Mn
Dec 31, 2019 -2.73 Mn
Sep 30, 2019 40.38 Mn
Jun 30, 2019 42.78 Mn
Mar 31, 2019 42.36 Mn
Dec 31, 2018 2.39 Mn
Jun 30, 2018 44.72 Mn
Dec 31, 2017 6.98 Mn